(5R)-5-benzylmorpholin-3-one | 1052210-00-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (5R)-5-benzylmorpholin-3-one
• 英文别名: (R)-5-Benzylmorpholin-3-one
• CAS: 1052210-00-0
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: PXPFDUZBGQDAEP-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5R)-5-benzylmorpholin-3-one 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以13%的产率得到(R)-3-苄基吗啉
  参考文献：
  名称：

  4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase

  摘要：

  4-(1,3-Thiazol-2-yl)morpholine derivatives have been identified as potent and selective inhibitors of phosphoinositide 3-kinase. The SAR data of selected examples are presented and the in vivo pro. ling of compound 18 is shown to demonstrate the utility of this class of compounds in xenograft models of tumor growth. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.076
• 作为产物：
  描述：

  2-chloro-N-[(2R)-1-hydroxy-3-phenylpropan-2-yl]acetamide 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 以53%的产率得到(5R)-5-benzylmorpholin-3-one
  参考文献：
  名称：

  4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase

  摘要：

  4-(1,3-Thiazol-2-yl)morpholine derivatives have been identified as potent and selective inhibitors of phosphoinositide 3-kinase. The SAR data of selected examples are presented and the in vivo pro. ling of compound 18 is shown to demonstrate the utility of this class of compounds in xenograft models of tumor growth. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.076

文献信息

• THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
  申请人：Lemieux Rene M.

  公开号：US20150031627A1

  公开（公告）日：2015-01-29

  Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

  提供的方法是治疗一种由IDH1/2突变等位基因特征性存在的癌症，包括向需要此治疗的患者施用此处描述的化合物。
• THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US20130190249A1

  公开（公告）日：2013-07-25

  Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

  提供了一种治疗具有IDH1/2突变等特征的癌症的方法，包括向需要的受试者施用此处描述的化合物。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20220098180A1

  公开（公告）日：2022-03-31

  The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

  本发明提供了一种具有HDAC抑制作用的杂环化合物，可用于治疗包括神经退行性疾病在内的中枢神经系统疾病等，以及包含该化合物的药物。本发明涉及一种由公式(I)表示的化合物，其中每个符号如描述中所述，或其盐。
• US9474779B2
  申请人：——

  公开号：US9474779B2

  公开（公告）日：2016-10-25
• US9850277B2
  申请人：——

  公开号：US9850277B2

  公开（公告）日：2017-12-26